Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
| ▸ | BCDIN3D | Q7Z5W3 | 3/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14373864 | 1.00 | SLC6A4 (0.47) | SLC6A4SHBGCES2CES1DPP4 | |
| SCHEMBL14373888 | 1.00 | SLC6A4 (0.47) | SLC6A4SHBGCES2CES1DPP4 | |
| Hydrochloric Acid SCHEMBL7780665 | 0.98 | SLC6A4 (0.46) | SLC6A4SHBGCES2CES1DPP4 | |
| SCHEMBL21784989 | 0.85 | SLC6A4 (0.46) | SLC6A4DPP4DPP8 | |
| SCHEMBL23560788 | 0.84 | SLC6A4 (0.44) | SLC6A4SHBGDPP4 | |
| SCHEMBL12261550 | 0.84 | SLC6A4 (0.44) | SLC6A4SHBGDPP4 | |
| Hydrochloric Acid SCHEMBL21248352 | 0.82 | SLC6A4 (0.43) | SLC6A4SHBGDPP4 | |
| SCHEMBL12261563 | 0.82 | SLC6A4 (0.43) | SLC6A4 | |
| Hydrochloric Acid SCHEMBL23527526 | 0.82 | SLC6A4 (0.43) | SLC6A4SHBGDPP4 | |
| SCHEMBL20811251 | 0.82 | SLC6A4 (0.43) | SLC6A4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Cadrenal Therapeutics, Inc. | 2019-10-17 | — | — | US | disclosed |
| WO-2018118705-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | EXITHERA PHARMACEUTICALS, INC. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2016131789-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-25 | — | — | WO | disclosed |
| EP-3056202-A1 | BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2016-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315711-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | KLK5, KLK2, KLKB1 | SLC6A4 4289/4885SHBG 660/4885CES2 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.